Skip to content

Study on drug safety in paediatrics of Hemocoagulase Agkistrodon based on real-world data

Study on drug safety in paediatrics of Hemocoagulase Agkistrodon based on real-world data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062100
Enrollment
Unknown
Registered
2022-07-22
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unlimited

Interventions

Case series:None

Sponsors

Children's Hospital Affiliated to Capital Institute of Pediatrics
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All hospitalized children who have used Hemocoagulase Agkistrodon.

Exclusion criteria

Exclusion criteria: 1.Dermatology; 2.Primary diseases: psoriasis, pemphigus, herpes zoster, systemic lupus erythematosus, allergic purpura, allergic pneumonia, allergic alveolitis, allergic vasculitis, allergic rhinitis with asthma, allergic enteritis, allergic diarrhea, allergic colitis, allergic asthma, acute allergic interstitial nephritis, adult still disease, juvenile still disease, dermatomyositis, vaginal Bowen disease, Raynaud disease, Kawasaki disease.

Design outcomes

Primary

MeasureTime frame
Adverse Drug Event;

Countries

China

Contacts

Public ContactTai Jun
121007886@qq.com+86 10 85695571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026